Intuitive Surgical (NASDAQ:ISRG) CEO Sells $13,414,975.00 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) CEO David Rosa sold 24,500 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $547.55, for a total value of $13,414,975.00. Following the completion of the transaction, the chief executive officer directly owned 234,256 shares in the company, valued at $128,266,872.80. The trade was a 9.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $537.59 on Thursday. The stock’s 50 day simple moving average is $461.96 and its 200 day simple moving average is $498.01. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The company has a market capitalization of $192.72 billion, a price-to-earnings ratio of 71.11, a PEG ratio of 5.01 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the business earned $1.84 EPS. The firm’s revenue was up 22.9% compared to the same quarter last year. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Institutional Trading of Intuitive Surgical

Several institutional investors have recently modified their holdings of ISRG. Chilton Capital Management LLC grew its holdings in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Tobam grew its position in Intuitive Surgical by 666.7% in the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 40 shares during the period. Elite Financial Inc. bought a new stake in Intuitive Surgical in the first quarter valued at $26,000. Kilter Group LLC bought a new stake in Intuitive Surgical in the second quarter valued at $27,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in Intuitive Surgical in the first quarter valued at $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the topic of a number of research analyst reports. The Goldman Sachs Group raised their target price on Intuitive Surgical from $567.00 to $621.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. UBS Group set a $600.00 target price on Intuitive Surgical and gave the company a “neutral” rating in a report on Thursday, October 23rd. Argus raised their target price on Intuitive Surgical from $600.00 to $630.00 in a report on Monday. Daiwa Capital Markets raised their target price on Intuitive Surgical from $510.00 to $550.00 and gave the company an “outperform” rating in a report on Friday, October 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Intuitive Surgical in a report on Friday, August 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $608.92.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.